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ttp://dx.doi.org/10.1016/j.ajpath.2013.05.020A frequently used experimentalmodel of chronic pancreatitis (CP) recapitulating humandisease is repeated
injection of cerulein into mice. C57BL/6 is the most commonly used inbred mouse strain for biomedical
research, but widespread demand has led to generation of several substrains with subtly different
phenotypes. In this study, two common substrains, C57BL/6J and C57BL/6NHsd, exhibited different
degrees of CP, with C57BL/6J being more susceptible to repetitive cerulein-induced CP as assessed by
pancreatic atrophy, pancreaticmorphological changes, andﬁbrosis.We hypothesized that the deﬁciency of
nicotinamide nucleotide transhydrogenase (NNT) protein in C57BL/6J is responsible for the more severe
C57BL/6J phenotype but the parameters of CP in NNT-expressing transgenic mice generated on a C57BL6/J
background do not differ with those of wild-type C57BL/6J. The highly similar genetic backgrounds but
different CP phenotypes of these two substrains presents a unique opportunity to discover genes important
in pathogenesis of CP. We therefore performed whole mouse genome Affymetrix microarray analysis of
pancreatic gene expression of C57BL/6J and C57BL/6NHsd before and after induction of CP. Genes with
differentially regulated expression between the two substrains that might be candidates in CP progression
included Mmp7, Pcolce2, Itih4, Wdfy1, and Vtn. We also identiﬁed several genes associated with devel-
opment of CP in both substrains, including RIKEN cDNA 1810009J06 gene (trypsinogen 5), Ccl8, and Ccl6.
(Am J Pathol 2013, 183: 692e708; http://dx.doi.org/10.1016/j.ajpath.2013.05.020)Supported by the President’s Research Fund (3-07821 to B.U. and
B.A.N.) and by a seed grant from the Frank R. Burton Memorial Fund
(B.U.), Saint Louis University.Chronic pancreatitis (CP) is an irreversible process char-
acterized by chronic inﬂammation, acinar cell loss, and
progressiveﬁbrosis of the pancreas.1 Identiﬁed risk factors for
the development of CP include alcoholism, smoking, auto-
immune injury, and hereditary factors.2 Activated pancreatic
stellate cells (PSCs) play a major role in the development of
pancreatic ﬁbrosis.3 The mechanism of CP is an area of active
investigation, and a variety of experimental animal models
of CP have been described.4 Repeated episodes of acute
pancreatitis induced by injecting the cholecystokinin analog
cerulein in mice induces CP similar to that of human CP,5,6
and this model is widely used to study the causes and treat-
ment of CP.
The C57BL/6 strain is the most commonly used mouse
strain in biomedical research, including research into thestigative Pathology.
.mechanism of CP. In experiments using genetically modiﬁed
C57BL/6mice, wild-typeC57BL/6mice are typically used as
experimental controls, on the assumption that the genetically
engineeredmice and control mice differ only in the artiﬁcially
altered genes. The validity of this assumption may depend
also on the substrain of the C57BL/6 mice used as compar-
ators. Multiple substrains of C57BL/6 mice have been pro-
duced through decades of propagation in different mouse
breeding facilities. Data have begun to accumulate that these
substrains have important genetic and phenotypic differences
and that they cannot be used interchangeably.7e10 Here, we
Cerulein-Induced CP Proﬁlereport major differences in the parameters of CP induced by
repetitive injection of cerulein between C57BL/6J mice (B6J)
from the Jackson Laboratory (Bar Harbor, ME) and C57BL/
6NHsd mice (B6N) from Harlan Laboratories (Indianapolis,
IN). The C57BL/6 strain was used to establish the B6J colony
at the Jackson Laboratory in 1948, and the B6J mice from the
Jackson Laboratory were subsequently used to establish
a C57BL/6 colony at the NIH in 1951. The B6N colony was
established by Harlan Laboratories from NIH stock in 1974.
Thus, the B6J and B6N colonies have been inbred separately
for more than six decades, allowing genetic divergence over
time.11 The most striking example of this divergence is
a spontaneous deletion in the B6J substrain causing the loss of
several exons and thereby loss of function of the nicotinamide
nucleotide transhydrogenase (Nnt) gene in B6J mice.12,13
In the present study, observed differences in the CP
phenotype of the closely related B6J and B6N substrains
provided a unique opportunity to identify candidate genes
that contribute to the development of CP. Because one
difference between these two substrains is the absence of
a functional NNT protein in B6J, we started by evaluating of
the role of NNT in the CP model. NNT is a nuclear encoded
mitochondrial inner membrane protein that plays a role in the
detoxiﬁcation of mitochondrial reactive oxygen species and
might be an essential factor in different pathological condi-
tions associated with mitochondrial dysfunction.13e15 Mito-
chondrial dysfunction has been shown to play a critical role
in the pathogenesis of pancreatic acinar cell injury, resulting
in pancreatitis.16,17 The NNT protein was therefore a rational
candidate for a contributor to pancreatitis susceptibility. To
analyze whether NNT expression is an important factor in
CP, we compared the course of cerulein-induced chronic and
acute pancreatitis of NNT-expressing transgenic mice on the
B6J Jackson background versus wild-type B6 mice (Nnt/).
We also sought to identify the spectrum of candidate genes
that might contribute to the difference in the severity of CP
between the two C57BL/6 substrains, and that may thus
represent CP susceptibility genes, by performing tran-
scriptome analysis of pancreatic tissues from B6J and B6N
mice before and after CP induction.
Materials and Methods
Animals
C57BL/6J (B6J) mice were obtained from the Jackson
Laboratory. C57BL/6NHsd (B6N) mice were obtained from
Harlan Laboratories. NNT-expressing transgenic mice on
the C57BL/6J background (Nntþ/þ) and C57BL/6J (Nnt/)
control mice were provided by MRC Harwell (Harwell,
UK). All mice were housed in standard facilities under
conditions of controlled temperature, humidity, and
a 12-hour light/dark cycle; mice were maintained on stan-
dard rodent chow with free access to water. Animal care and
all procedures were approved by the Institutional Animal
Care and Use Committee of Saint Louis University. MiceThe American Journal of Pathology - ajp.amjpathol.orgobtained from commercial vendors were kept in the Saint
Louis University animal facility for 2 weeks before the start
of experiments. Nnt/ and Nntþ/þ mice were propagated at
the Saint Louis University animal facility to obtain sufﬁcient
numbers of mice for conducting the experiments. Geno-
typing was performed as described below.
Experimental Model of CP and Tissue Processing
CP was induced in 8-week-old B6J and B6N female mice
(18 to 20 g body weight) by repeated intraperitoneal injec-
tions of cerulein (Sigma-Aldrich, St. Louis, MO), 50 mg/kg
hourly, as described previously.18 Six hourly injections
given in one day constituted one treatment. Treatments were
given every other day for a total of three treatments. Sex-
and age-matched control mice received comparable injec-
tions of saline. To allow resolution of acute changes, mice
were euthanized by CO2 asphyxiation at 3 days after their
ﬁnal cerulein treatment. Each pancreas was removed,
weighed, and divided into three sections. One section was
ﬁxed in 10% neutral buffered formalin solution (Sigma-
Aldrich) for histological analysis, another was immediately
frozen in liquid nitrogen and stored at 80C for subse-
quent protein extraction and Western blot analysis, and the
third portion was placed in an RNA-stabilizing solution
(Ambion RNAlater; Life Technologies, Carlsbad, CA) and
stored overnight at 4C for RNA isolation and subsequent
real-time quantitative PCR (qPCR) analysis.
Experimental Model of Acute Pancreatitis and Tissue
Processing
Toevaluate acute injury, 8-week-old femaleB6J andB6Nmice
were subjected to a single cerulein treatment (ie, six hourly
injections of 50 mg/kg each), and at 9 hours after the ﬁrst cer-
ulein injection the mice were euthanized by CO2 asphyxiation.
Sex- and age-matched control mice received comparable
injections of saline solution. Each pancreas was removed,
weighed, and placed in 10% neutral buffered formalin solution
(Sigma-Aldrich) for histological analysis. Blood was collected
at this time for measuring plasma amylase activity.
Histology Analysis
Formalin-ﬁxed pancreatic tissues were embedded in parafﬁn,
sectioned, and stained with H&E using standard protocols for
microscopic evaluation. Slides were graded by an experienced
pathologist (K.O.) masked to treatment group and substrain
using a semiquantitative histopathology scoring system
similar to one that we have described previously.18,19 In the
grading system used for the analysis of slides after induction of
CP, within the pancreatic sections any areas of abnormal
architecture were estimated as a percentage of the normal area.
Within these abnormal areas, necrosis was graded as 0 Z
absent, 1Z minimal (<10%), 2Z moderate (10% to 50%),
and 3 Z severe (>50%). In addition, the presence of acute693
Ulmasov et alinﬂammatory cells (mainly neutrophils) and chronic inﬂam-
matory cells (mononuclear cells) was graded as 0Z absent, 1
Zminimal, 2Zmild, 3Zmoderate, and 4Z severe. H&E-
stained pancreatic sections obtained at 9 hours after induction
of acute pancreatitis were graded on four criteria, vacuoliza-
tion, necrosis, inﬂammation, edema, on the following scales.
Vacuolization was graded as 0 Z absent, 1 Z 5% to 14%,
2Z 15% to 35%, 3Z 35% to 50%, and 4Z>50%. Necrosis
was graded as 0Z absent, 1Z periductal necrosis<5%, 2Z
focal necrosis 5% to 20%, and 3Z diffuse periductal necrosis
20% to 50%. Inﬂammation was graded as 0 Z absence of
inﬂammatory inﬁltrates, 1 Z inﬂammatory inﬁltration in
ducts, 2 Z inﬂammatory inﬁltration in the parenchyma
<50%, and 3Z inﬂammatory inﬁltration in the parenchyma
>50%. Edema was graded as 0 Z absent, 1 Z focally
increased between lobules, 2 Z diffusely increased between
lobules, and 3Z acini disrupted and separated.
To evaluate pancreatic collagen content, parafﬁn-
embedded pancreatic sections were stained with Sirius Red
(F3B) solution, as we have described previously.18 The extent
of collagen accumulation was evaluated by morphometric
analysis20 as we have detailed previously,18,19 relative to the
amount of collagen in the saline-treated controls.
Western Blotting
To obtain pancreatic protein, frozen pancreatic tissues were
homogenized in ice-cold radioimmunoprecipitation assay
buffer containing 150 mmol/L NaCl, 50 mmol/L Tris-HCl,
pH 7.4, 1 mmol/L EDTA, 1% NP-40, 0.1% SDS, 0.5%
sodium deoxycholic acid, and a freshly added mixture of
proteinase inhibitor cocktail (Sigma-Aldrich). Total protein
extract (20 mg) was resolved by SDS-PAGE and blotted to
Immobilon-P polyvinylidene diﬂuoride transfer membranes
(EMD Millipore, Billerica, MA). Blots were blocked in 5%
nonfat dried milk in TBST buffer (10 mmol/L Tris-HCl, pH
7.4, 0.9% NaCl, and 0.05% Tween 20) and were probed
with primary antibody. a-SMA protein was detected with
monoclonal antiea-SMA antibody (Sigma-Aldrich). For
the loading control, blots were probed with an antibody to
extracellular signal-regulated kinase 1/2 (ERK1/2) [ERK 1Table 1 GenBank Accession Numbers and Primer Sequences of Mouse
Gene Accession no. Forward sequence
1810009J06Rik NM_023707 50-GTTCGCCTTGGTGA
Rplp0 NM_007475 50-AGATTCGGGATATG
C4b NM_009780 50-AATAACCTGGGTCG
Ccl8 NM_021443 50-CTGGGCCAGATAAG
Itih4 NM_018746 50-CCTCCGTTGCAGCA
Pcolce2 NM_029620 50-TGTGGCGGCATTCT
Acta2 NM_007392 50-GTCCCAGACATCAG
Vim NM_011701 50-TCCACACGCACCTA
Vtn NM_011707 50-CCCCTGAGGCCCTT
Wdfy1 NM_027057 50-ACCATCCGAGTATG
Acta2, alpha2, smooth muscle, aorta; C4b, complement component 4B (Chido b
inhibitor, heavy chain 4; Pcolce2, procollagen C-endopeptidase enhancer 2; 18100
protein, large, P0 [alias acidic ribosomal protein P0 (Arbp)]; Vim, vimentin; Vtn,
694antibody (C-16); Santa Cruz Biotechnology, Santa Cruz,
CA]. ERK1/2 is an established loading control for quanti-
ﬁcation of pancreatic proteins after cerulein-induced chronic
and acute pancreatitis.21,22 NNT protein was detected using
a custom-made (Eurogentec, Liege, Belgium) polyclonal
NNT antibody,23 and a polyclonal b-actin antibody (Santa
Cruz Biotechnology) was used as a loading control. Signals
were developed using horseradish peroxidaseeconjugated
anti-mouse IgG (Sigma-Aldrich) for a-SMA and anti-rabbit
IgG (Santa Cruz Biotechnology) for NNT, ERK1/2, and b-
actin, with Amersham ECL Plus Western blotting detection
reagent (GE Healthcare, Little Chalfont, UK). Protein band
intensities were quantiﬁed using a Personal Densitometer
SI, Model 375 (Molecular Dynamics, Sunnyvale, CA) and
ImageJ software version 1.37 (NIH, Bethesda, MD).
Genomic DNA Extraction and the NNT Mutation
Detection
Genomic DNA was isolated from the mouse tail snips by
overnight digestion in 500 mL of lysis buffer (100 mmol/L
Tris-HCl, pH 8.5, 5 mmol/L EDTA, 0.2% SDS, 200 mmol/L
NaCl) containing 0.6mg/mLof proteinaseK (Sigma-Aldrich)
at 50C. After the incubation, samples were centrifuged at
14,000  g, and DNA was precipitated from the supernatant
by isopropanol, washed with 70% ethanol, and resuspended
in 200mLof TE buffer (10mmol/L Tris-HCl, pH 8.0, 1mmol/
L EDTA). Three microliters of the solution was used in each
PCR reaction. Primer sequences for the detection of the
Nnt mutation were based on the sequences in the Primer
Bank (http://pga.mgh.harvard.edu/primerbank, last accessed
March 2, 2010)24: forward primer, 50-GGGTCAGTTGT-
TGTGGATTTAGC-30; reverse primer, 50-GCCTTCAGGA-
GCTTAGTGATGTT-30. The correspond-ing amplicon is in
exons 7 and 8, which are deleted in B6Jmice. The expected size
of the PCR product in B6N mice is 732 bp.
Mitochondria Isolation
Mitochondrial fractions were isolated from the frozen
pancreatic tissues using a Pierce mitochondrial isolation kitGenes Evaluated by qPCR
Reverse sequence
ACACAAT-30 50-GGATGGCAGGTGACTTCAATTT-30
CTGTTGGC-30 50-TCGGGTCCTAGACCAGTGTTC-30
GACTTTGG-30 50-CTCCGTCAGGGACGATGTTG-30
GCTCC-30 50-CATGGGGCACTGGATATTGTT-30
CAATATC-30 50-GCGGCAAGGTAATAGTAGGAAC-50
TACCG-30 50-CCCTCAGGAACTGTGATTTTCCA-30
GGAGTAA-30 50-TCGGATACTTCAGCGTCAGGA-30
CAGTCT-30 50-CCGAGGACCGGGTCACATA-30
TTTCATA-30 50-CAAAGCTCGTCACACTGACA-30
GCTGAAA-30 50-CCTGCTGTCGTGGTGGTATG-30
lood group); Ccl8, chemokine (C-C motif) ligand 8; Itih4, inter alpha-trypsin
09J06Rik, RIKEN cDNA 1810009J06 gene (trypsinogen 5); Rplp0, ribosomal
vitronectin; Wdfy1, WD repeat and FYVE domain containing 1.
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Figure 1 Severity of cerulein-induced CP in B6N and B6J substrains.
Mice were subjected to three episodes of cerulein treatment over 5 days to
induce CP and were sacriﬁced at 3 days after the last treatment. A: Loss of
pancreatic weight relative to total body weight indicates signiﬁcant
pancreatic atrophy. B6J mice have signiﬁcantly more pancreatic atrophy,
compared with B6N mice. B: Histological changes in H&E-stained pancreas
of B6N and B6J mice after induction of CP. Pancreas from B6N and B6J
mice after control saline treatment shows no abnormalities. After cerulein
treatment, pancreas from both B6J and B6N mice shows disrupted acinar
architecture, dedifferentiation to tubular complexes, and interstitial
inﬂammation; all of these parameters were more severe in B6J than B6N
mice (Table 2). Data are expressed as means  SEM. nZ 6 mice per group.
***P < 0.001. Original magniﬁcation, 200.
Table 2 Severity of Cerulein-Induced CP in B6N and B6J Mice
Histopathology*
No cerulein Cerulein
PB6N B6J B6N B6J
% Abnormal
architecture
0  0 0  0 14  5.5 28  2.7 0.008
Necrosis 0  0 0  0 1.8  0.45 2.0  0 1.00
Acute
inﬂammation*
0  0 0  0 1  0 2  0 0.008
Chronic
inﬂammationy
0  0 0  0 2  0 2.6  0.55 0.151
Histopathology was scored as described under Materials and Methods.
Higher values indicate greater severity. Data are expressed as means 
SEM. n Z 5 mice per group. P values were calculated between cerulein-
treated B6N and B6J mice.
*For acute inﬂammation, the content of acute inﬂammatory cells
(neutrophils) was graded.
yFor chronic inﬂammation, the content of mononuclear cells was graded.
Cerulein-Induced CP Proﬁlefor tissue (Thermo Fisher Scientiﬁc, Rockford, IL) according
to the manufacturer’s instructions. Five micrograms of total
mitochondrial protein was used for the Western blot analysis.
qPCR Analysis
Total RNA was prepared from pancreatic tissues stabilized
in Ambion RNAlater solution (Life Technologies) by
extraction with TRIzol reagent (Life Technologies) ac-
cording to the manufacturer’s protocol. The concentration
and purity of isolated RNA was estimated by measuring
absorbances at 260 and 280 nm using a NanoDrop ND-1000The American Journal of Pathology - ajp.amjpathol.orgspectrophotometer (Thermo Fisher Scientiﬁc, Wilmington,
DE). For qPCR assay, 2 mg of total RNA was treated with
Turbo DNase (Life Technologies) and reverse-transcribed to
cDNA using a high-capacity RNAeto-cDNA kit (Life
Technologies). qPCR was performed with a 7500 real-time
PCR System (Life Technologies) using SYBR Green real-
time PCR ReadyMix Low Rox (Sigma-Aldrich) according
to the manufacturer’s instructions. PCR primers were
synthesized by Life Technologies based on the sequences
from Primer Bank.24 The primer sequences of transcripts
evaluated by qPCR are listed in Table 1. Threshold cycle
numbers were determined using Applied Biosystems 7500
software version 2.05 (Life Technologies). Ampliﬁcation
products were veriﬁed by melting curves. The efﬁciency of
ampliﬁcation for each set of primers was tested by a serial
dilution of the templates and corresponded to a two-fold
increase per ampliﬁcation cycle. Control reactions in the
absence of template were used as negative controls. Results
were calculated with normalization to ribosomal protein,
large, P0 (Rplp0) mRNA. Rplp0 [alias acidic ribosomal
phosphoprotein P0 (Arbp)] was chosen as the housekeeping
gene because it was previously demonstrated that its mRNA
does not change signiﬁcantly with single or multiple
episodes of cerulein-induced pancreatitis.18,25e27 The com-
parative threshold cycle method28 was used to calculate
changes in mRNA abundance.
Microarrays
TotalRNAwas isolated frompancreatic tissues ofB6J andB6N
mice at day 10 after induction of CP by repetitive cerulein
treatment and from saline-treated B6J and B6N controls. To
prepare total RNA, pancreatic tissue in RNA stabilization
solution (Ambion RNAlater; Life Technologies) was ﬁrst
extracted with TRIzol reagent (Life Technologies) according to
the manufacturer’s instructions and then further puriﬁed using
an RNeasy mini kit (Qiagen, Valencia, CA). RNA integrity
was conﬁrmed with an Agilent 2100 bioanalyzer (Agilent695
Figure 2 Collagen content in the pancreas assessed by Sirius Red
staining after induction of CP by repetitive cerulein injections. A: Repre-
sentative pancreatic sections of pancreas from saline-treated control B6N
and B6J mice and from cerulein-treated B6N and B6J mice. Control mice
exhibit some perilobular collagen, with no difference between substrains.
Cerulein-treated mice demonstrate extensive interlobular and periacinar
collagen staining, indicating robust ﬁbrogenesis in this model of CP.
Collagen staining was more pronounced in B6J than in B6N mice. B:
Quantiﬁcation by morphometric analysis showed that the relative amount
of pancreatic collagen was greater in B6J than in B6N mice. Data are
expressed as means  SEM. n Z 6. *P Z 0.0005. Original magniﬁcation,
200.
Figure 3 Activation of PSCs after induction of CP. A: Western blotting
of pancreatic extracts demonstrated increased expression of a-SMA,
a marker of PCS activation, in both B6N and B6J mice. ERK1/2 was used as
a loading control. B: Densitometric analysis of a-SMA protein expression
after induction of CP. An increase in a-SMA expression was observed for
B6J mice, compared with B6N mice, but the difference did not reach
statistical signiﬁcance (P Z 0.9). Data are expressed as means  SEM.
n Z 5 mice per group.
Ulmasov et alTechnologies, Santa Clara, CA), and concentrations were
measured using a NanoDrop ND-1000 spectrophotometer
(Thermo Fisher Scientiﬁc, Wilmington, DE). Samples of 200
mg of total RNA were reversed-transcribed and then ampliﬁed
by in vitro transcription according to the Affymetrix (Santa
Clara, CA) standard protocol. Mouse Affymetrix GeneChip
MouseGenome 430.2.0 arrays were used for all hybridizations.
These arrays contain probes representing more than 39,000
mouse transcripts. Four groups (cerulein-treated B6J, cerulein-
treated B6N, saline-treated B6J, and saline-treated B6N) were
each analyzed in triplicate (12 microarrays total). Microarray
data were normalized and statistically analyzed using the
Affymetrix Expression Console version 1.2 (Santa Clara, CA),
R/Bioconductor version 2.7 (http://www.bioconductor.org,
last accessed October 19, 2011), and Partek Genomics Suite
version 6.5 (Partek, St. Louis, MO) software packages.
Microarray hybridization and analysis were performed at
the microarray core facility of Saint Louis University.696Pathway analysis was performed using DAVID (Database for
Annotation, Visualization and Integrated Discovery) Bio-
informatic Resources version 6.7 (http://david.abcc.ncifcrf.
gov/home.jsp, last accessed January 12, 2012).29 The data
discussed in this publication have been deposited in the NCBI
Gene Expression Omnibus30 and are accessible through GEO
series (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?accZ
GSE41418; accession number GSE41418).
Pancreatic Stellate Cell Isolation and Culture
Pancreata of 7- to 9-week-old mice (nZ 9 for each B6N and
B6J substrain) were combined for PSC isolation. PSCs were
isolated using collagenase digestion and gradient centrifuga-
tion as we have described previously.19 Isolated cells were
plated on 100-mm plastic culture plates and were maintained
in 10% fetal bovine serum in Dulbecco’s modiﬁed Eagle’s
medium (Sigma-Aldrich) with antibiotics (Penicillin, 100
units, Streptomycin, 0.1 mg/mL) in a humidifying incubator
with a 5% CO2eenriched atmosphere at 37

C. PSCs were
cultured for 9 days, plated on 12-well plates (Corning, Corn-
ing, NY), and cultured for another 48 hours. Cells were serum
starved for 48 hours; RNA was then extracted using TRIzol
reagent (Life Technologies) and used for the qPCR analysis.ajp.amjpathol.org - The American Journal of Pathology
Figure 4 Parameters of acute pancreatic injury in B6J and B6N substrains. Mice were subjected to a single episode of acute pancreatitis (six hourly
injections in one day) and were sacriﬁced at 9 hours after the ﬁrst cerulein injection. Saline-injected mice were used as controls. A: Pancreatic edema,
measured as the ratio of pancreatic weight to body weight, showed similar increases in B6N and B6J mice. B: Plasma amylase levels were also elevated similarly
in B6N and B6J mice. C: Histological changes in the pancreas were evaluated by H&E staining. Pancreas from saline-treated mice appeared normal, whereas the
pancreas from cerulein-treated mice showed acute injury including vacuolization, inﬂammatory cell inﬁltration, and necrosis. Data are expressed as means 
SEM. n Z 6 mice per group. **P < 0.01. Original magniﬁcation, 200.
Cerulein-Induced CP ProﬁleStatistical Analysis
Nonparametric U-test was used for statistical analysis of
histological measures of chronic and acute pancreatitis.
Statistical analysis of all other experiments was performed
using one-way analysis of variance followed by two-tailed t-
test. P values of <0.05 were considered to be statistically
signiﬁcant (SigmaStat software version 3.1, San Jose, CA).
For qPCR results, DCT values were used for statistical
analysis, as recommended.31 Data are expressed as means 
SEM or as means with conﬁdence intervals.
Results
Cerulein-Induced CP Is More Severe in B6J than in B6N
Mice
CP was induced in groups of B6J and B6N mice by repetitive
cerulein treatment. Saline-treated mice were used as controls.
The ratios of pancreatic weight to body weight, as well as
histological changes, were evaluated to assess pancreatic
atrophy, inﬂammation, and ﬁbrosis. Pancreatic weights were
signiﬁcantly lower in cerulein-treated groups, compared
with control mice, indicating signiﬁcant organ atrophy with
repetitive injury. B6Jmicewere found to havemore pancreaticTable 3 Similar Severity of Cerulein-Induced Acute Pancreatic
Injury in B6N and B6J Mice
Histopathology
No cerulein Cerulein
B6N B6J B6N B6J
Vacuolization 0  0 0  0 3.0  0 3.0  0
Necrosis 0  0 0  0 2.0  0.82 2.25  0.5
Inﬂammatory
inﬁltration
0  0 0  0 1.5  0.58 2  0
Edema 0  0 0  0 1.25  0.5 1.0  0
Histopathology was scored as described under Materials and Methods.
Higher values indicate greater severity. Data are expressed as means 
SEM. n Z 5 mice per group. No signiﬁcant differences were detected.
The American Journal of Pathology - ajp.amjpathol.orgatrophy after cerulein treatment, compared with B6N mice
(Figure 1A). Morphological changes in the pancreas were
assessed by H&E staining (Figure 1B and Table 2). In the
untreated mice, the acinar units were tightly packed, and there
were no apparent differences between B6N and B6J mice
(Figure 1B). Repetitive cerulein treatment caused signiﬁcant
morphological alterations, including disruption of acinar cell
architecture and inﬂammatory cell inﬁltration. These alter-
ations were more severe in cerulein-treated B6J mice than inFigure 5 B6J mice are nicotinamide nucleotide transhydrogenase
(NNT) deﬁcient. A: PCR analysis of genomic DNA from B6J and B6N mice
conﬁrmed that B6J mice lack the Nnt gene. B: Western blotting of
pancreatic extracts demonstrated the presence of NNT protein in B6N and
its absence in B6J mice. b-Actin was used as in internal control.
697
Figure 6 Western blot of pancreatic mitochondrial nicotinamide
nucleotide transhydrogenase (NNT) protein, conﬁrming absence of
expression in B6J mice and similar expression in B6J Nntþ/þ transgenic
mice and B6J mice.
Ulmasov et alB6N mice, as assessed by masked evaluation (Table 2 and
Figure 1B).
Fibrosis Associated with CP Is Greater in B6J than in
B6N Mice
Pancreatic damage in CP is associated with pancreatic ﬁbro-
genesis, a process that may interfere with normal regeneration
and organ function just as it does in the liver. We used Sirius
Red staining of pancreatic sections as a measure of collagen
deposition and found increased collagen content of cerulein-
treated B6J mice, compared with B6N mice (Figure 2A). To
quantify these ﬁbrotic changes, the extent of Sirius Red
staining was evaluated with morphometric image analysis
(Figure 2B). This analysis demonstrated that the amount of
pancreatic SiriusRed-positive stainingwas higher in B6Jmice
than in B6Nmice. PSCs play a key role in extracellular matrix
deposition and pancreatic ﬁbrosis. In response to injury,
PSCs develop an activated myoﬁbroblast-like phenotype withTable 4 Differential Expression of Pancreatic Genes in B6J and B6N M
Gene name Gene sy
UDP glucuronosyltransferase 2 family, polypeptide B34 Ugt2b34
Ectonucleoside triphosphate diphosphohydrolase 4 Entpd4
Immunoglobulin lambda variable 1 Iglv1
Complement component 4B (Chido blood group)* C4b
Nicotinamide nucleotide transhydrogenase Nnt
Inter alpha-trypsin inhibitor, heavy chain 4* Itih4
WD repeat and FYVE domain containing 1* Wdfy1
A transcript was considered to be highly signiﬁcantly divergently expressed bet
the average fold change was >2. A minus sign in the fold difference column ind
*Signiﬁcantly altered after cerulein treatment in the CP mouse model.
698increased a-SMA accumulation. The level of a-SMA protein
varied among similarly treated mice and showed a trend
toward being greater in B6Jmice than in B6Nmice (Figure 3).
Degree of Acute Pancreatic Injury Induced by Cerulein
Is Similar in B6J and B6N Mice
To assess the possibility that the difference in the degree of CP
between B6J and B6N mice arises from differences in the
degree of acute cerulein-induced injury, we compared the
parameters of acute pancreatic injury after a single episode of
cerulein treatment. As a measure of acute pancreatic injury,
the following parameters were evaluated: pancreatic edema
(ratio of pancreatic weight to mouse weight), plasma level of
amylase, and histological scoring of H&E-stained pancreatic
sections at 9 hours after the ﬁrst cerulein injection (Figure 4).
Pancreatic edema and plasma amylase levels increased
signiﬁcantly after acute pancreatic injury with no differences
between B6J and B6N substrains (Figure 4, A and B).
Histological manifestations of acute pancreatic injury as
assessed by masked scoring were also not signiﬁcantly dif-
ferent between B6N and B6J mice (Figure 4C and Table 3).
Absence of NNT Protein in B6J Mice Is Not Responsible
for the More Severe CP
We conﬁrmed the deletion of the Nnt gene in B6J mice
obtained from the Jackson Laboratory by PCR ampliﬁcation
of genomic DNA using primers designed to span the deleted
exons (Figure 5A). The expression of NNT protein in the
pancreas of B6N mice and the absence of such expression in
the pancreas of B6J mice was conﬁrmed by Western blot
analysis (Figure 5B).
To determine whether the absence of NNT expression in
B6J mice contributes to the more severe CP phenotype in
this substrain, we compared the degree of cerulein-induced
CP in B6J mice and transgenic mice expressing NNT
protein on the B6J background. The NNT transgenic mice
were generated previously at MRC Harwell, to investigate
the role of NNT protein in glucose intolerance in B6J
mice.23,32 Those studies demonstrated that transgenicouse Substrains in the Normal Pancreas
mbol EntrezGene ID Chr
Fold difference
B6J vs B6N
100727 5 3.0
67464 14 2.3
16142 16 8.0
12268 17 5.7
18115 13 2.8
16427 14 2.8
69368 1 2.0
ween B6J and B6N substrains if the P value between strains was <0.01 and
icates lower mRNA abundance in B6J versus B6N. Chr, chromosome.
ajp.amjpathol.org - The American Journal of Pathology
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Figure 7 Pancreatic Itih4 expression in B6J and B6N substrains. A:
Itih4 mRNA expression in the pancreas after induction of CP was much
lower in B6J mice than in B6N mice under control conditions of saline
injections. After induction of CP, pancreatic Itih4 expression was markedly
down-regulated in both substrains, but its expression was higher in B6N
than in B6J. B: Itih4 mRNA expression in the pancreas 9 hours after the
acute injury induced by one cerulein treatment. Acute injury did not
decrease Itih4 mRNA expression. Itih4 mRNA expression was normalized to
Rplp0 and expressed as fold increase over the level in B6N saline-treated
control mice. Data are expressed as means with 95% conﬁdence inter-
vals. Conﬁdence intervals were calculated using the DCT values before
exponential transformation to fold increase in mRNA and are therefore
asymmetric about the means. n Z 6. *P < 0.05.
Cerulein-Induced CP Proﬁleexpression of NNT in B6J mice rescued the B6J glucose-
intolerance phenotype, indicating that transgenic mice
express functional NNT protein. To conﬁrm that transgenic
B6J mice express NNT protein in mitochondria at a level
similar to that of B6N mice, we performed Western blot
analysis of NNT protein from isolated pancreatic mito-
chondria. The results conﬁrmed that similar levels of NNT
protein are expressed in NNT transgenic mice and B6N
mice (Figure 6).
To investigate the role of NNT in CP, CP was induced
in wild-type B6J mice (Nnt/) and NNT transgenic mice
(Nntþ/þ) on the same B6J background using repetitive cer-
ulein treatment (6 or 7mice per group). Sex- and age-matched
groups ofNnt/ andNntþ/þmice were used as saline-treated
controls. Although repetitive cerulein treatment caused
signiﬁcant pancreatic damage andﬁbrosis, we did notﬁnd any
differences in any of the parameters (measured as described in
the previous section for B6J andB6Nmice) between cerulein-
treated Nnt/ and Nntþ/þ mice (data not shown), indicating
that the presence of NNT in the transgenic mice was not
protective against CP and that the substrain difference in CP
severity is not due to the absence of NNT in B6J mice.
Substrain Differences in mRNA Expression of Other
Genes in the Normal Pancreas
To explore the differences in expression of other genes in
the two substrains after injury, we ﬁrst determined whether
there were differences in gene expression in these mice
under basal conditions without any treatment. Affymetrix
microarray analysis of pancreatic mRNA from normal
pancreas of B6N and B6J mice revealed that most of the
mRNAs from these two substrains were expressed at similar
levels. Nevertheless, seven mRNAs (including NNT)
exhibited signiﬁcant differences between substrains, with
more than twofold change (P < 0.01) in their expression as
assessed by microarray (Table 4). The presence of detect-
able NNT mRNA on the microarray in B6J mice has been
attributed to the presence of a short truncated unstable
mRNA transcript that does not lead to production of func-
tional NNT protein in this substrain.13 The difference in
gene expression under basal conditions identiﬁed on the
microarray was conﬁrmed by qPCR for Itih4 (Figure 7A).
Pancreatic Gene Expression Proﬁle Associated with
Cerulein-Induced CP in B6N and B6J Substrains
Induction of CP caused signiﬁcant changes in the pattern of
pancreatic gene expression in both B6N and B6J substrains,
as determined by comparing pancreatic mRNA expression
before and after the repetitive cerulein treatment, using
microarray analysis. On average, close to 7% of genes were
up-regulated and approximately 0.7% of genes were down-
regulated more than twofold (P < 0.01) after repetitive
cerulein treatment in both substrains. The genes identiﬁed
by this analysis were involved mainly in eight cellularThe American Journal of Pathology - ajp.amjpathol.orgpathways: cell cycle, DNA replication and repair, focal
adhesion, ﬁbrosis, ubiquitin-mediated proteolysis, cancer,
apoptosis, and immune response. Genes that were differ-
entially regulated by more than 10-fold (P < 0.01) in one or
both of the substrains after induction of CP are listed in
Table 5. Genes associated with ﬁbrosis that were differen-
tially regulated to the greatest degree included collagen,
type V, alpha 2 (Col1a2); collagen, type III, alpha 1
(Col3a1); collagen, type V, alpha 2 (Col5a2); CD44 antigen
(Cd44); inter alpha-trypsin inhibitor heavy chain 4 (Itih4),
and matrix metalloproteinases 2 and 7 (Mmp2 and Mmp7).
To determine whether gene expression proﬁles associated699
Table 5 Highly Differentially Regulated Pancreatic Genes in the Cerulein-Induced Model of CP
Gene Gene symbol EntrezGene ID Chr
Fold change, CP vs
control B6J; B6N
Adenylate cyclase 7 Adcy7 11513 8 11.3; 3.5
Alpha 1 microglobulin; bikunin Ambp 11699 4 12.9; 10.0
Annexin A10* Anxa10 26359 8 28.0; 10.8
Anterior gradient 2 Agr2 23795 12 38.8; 21.9
Antigen identiﬁed by monoclonal antibody Ki 67 Mki67 17345 7 10.0; 4.5
Apolipoprotein E Apoe 11816 7 13.0; 14.4
Asporin* Aspn 66695 13 11.4; 2.5
Baculoviral IAP repeat-containing 5 Birc5 11799 11 30.3; 20.3
Biglycan Bgn 12111 X 10.9; 3.2
Carbonic anhydrase 9 Car9 230099 4 11.0; 6.8
Cartilage intermediate layer protein, nucleotide pyrophosphohydrolase Cilp 214425 9 23.7; 27.0
Cathepsin K Ctsk 13038 3 11.3; 12.4
Cathepsin S Ctss 13040 3 13.9; 11.9
CD14 antigen Cd14 12475 18 10.3; 8.2
CD44 antigen Cd44 12505 2 13.6; 12
CD52 antigen Cd52 23833 4 10.9; 5.8
CDC28 protein kinase 1b Cks1b 54124 3 14.4; 11.8
CDC28 protein kinase regulatory subunit 2 Cks2 66197 4 10.3; 11.3
Cell division cycle 20 Cdc20 107995 4 10.8; 7.5
Centromere protein A Cenpa 12615 5 10.0; 8.0
Ceruloplasmin Cp 12870 3 4.8; 11.5
Chemokine (C-C motif) ligand 6 Ccl6 20305 11 11.9; 3.5
Chemokine (C-C motif) ligand 8* Ccl8 20307 11 61.5; 12.9
Claudin 2 Cldn 12738 X 20.1; 23.4
Complement component 1, q subcomponent, beta polypeptide C1qb 12260 4 13.7; 7.2
Complement component 1, q subcomponent, C chain C1qc 12262 4 14.6; 13.4
Complement component 3a receptor 1 C3ar1 12267 6 4.1; 10.1
Complement component factor i Cﬁ 12630 3 8.4; 13.7
Cyclin-dependent kinase 1 Cdk1 12534 10 11.3; 7.4
DNA segment, Chr 17, human D6S56E5 D17H6S56E-5 110956 17 20.0; 35.3
EGF-like module containing, mucin-like, hormone receptor-like
sequence 1
Emr1 13733 17 11.0; 8.5
Expressed sequence AU020206 AU020206 101757 7 7.1; 12.5
Fc receptor, IgE, high afﬁnity I, gamma polypeptide Fcer1g 14127 1 12.3; 6.1
Fc receptor, IgG, low afﬁnity Iib Fcgr2b 14130 1 11.6; 7.6
Flap structure speciﬁc endonuclease 1 Fen1 14156 19 5.6; 10.3
Gastric intrinsic factor Gif 14603 19 15.2; 16.3
Group speciﬁc component Gc 14473 5 17.1; 9.4
Growth arrest speciﬁc 5 Gas5 14455 1 8.2; 17.7
Helicase, lymphoid speciﬁc Hells 15201 19 10.7; 4.5
Hexosaminidase B Hexb 15212 13 10.4; 9.9
Integral membrane protein 2A Itm2a 16431 X 15.9; 17.3
Inter-alpha (globulin) inhibitor H5 Itih5 209378 2 4.6; 11.5
Interferon activated gene 203 Iﬁ203 15950 1 10.3; 8.3
Interferon, alpha-inducible protein 27 like 2A* Iﬁ27l2a 76933 12 10.0; 2.6
Interferon activated gene 205 Iﬁ205 226695 1 10.5; 6.7
Lectin, galactose binding, soluble 3 Lgals3 16854 14 16.8; 12.3
Legumain Lgmn 19141 12 10.0; 8.4
Lipocalin 2 Lcn2 16819 2 25.0; 19.1
Lumican Lum 17022 10 12.6; 14.1
Lymphocyte antigen 86 Ly86 17084 13 14.3; 8.0
Lysozyme 1 Lyz1 17110 10 11.6; 9.6
Lysozyme 2 Lyz2 17105 10 15.3; 11.3
Lysyl oxidase Lox 16948 18 10.1; 8.6
Macrophage expressed gene 1 Mpeg1 17476 19 11.1; 15.4
Major urinary protein 2 Mup2 17841 4 31.2; 53.4
(table continues)
Ulmasov et al
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Table 5 (continued )
Gene Gene symbol EntrezGene ID Chr
Fold change, CP vs
control B6J; B6N
Matrix Gla protein Mgp 17313 15 9.6; 11.1
Matrix metallopeptidase 2 Mmp2 17390 8 10.0; 16.2
Matrix metallopeptidase 7* Mmp7 17393 9 16.0; 3.8
Membrane-spanning 4-domains, subfamily A, member 6B Ms4a6b 69774 19 14.3; 8.3
Membrane-spanning 4-domains, subfamily A, member 7 Ms4a7 109225 19 29.5; 25.9
Mesoderm speciﬁc transcript Mest 17294 6 10.8; 12.7
Minichromosome maintenance deﬁcient 4 homolog (S. cerevisiae) Mcm4 17217 16 8.8; 19.1
Minichromosome maintenance deﬁcient 5, cell division cycle 46
(S. cerevisiae)
Mcm5 17218 8 23.0; 17.8
Minichromosome maintenance deﬁcient 6 (MIS5 homolog,
S. pombe) (S.cerevisiae)
Mcm6 17219 1 22.8; 19.5
Minichromosome maintenance deﬁcient 7 (S. cerevisiae) Mcm7 17220 16 10.4; 6.6
Non-SMC condensin II complex, subunit G2 Ncapg2 76044 12 10.5; 7.2
Osteoglycin Ogn 18295 13 12.7; 6.7
PDZ binding kinase Pbk 52033 14 12.3; 9.7
Periostin, osteoblast speciﬁc factor Postn 50706 3 37.8; 40.7
Placenta-speciﬁc 8 Plac8 231507 5 11.8; 5.8
Pleckstrin homology-like domain, family B, member 2 Phldb2 208177 16 10.2; 13.2
Pleiotrophin Ptn 19242 6 10.0; 12.3
Procollagen, type I, alpha 2 Col1a2 12843 6 6.3; 11.2
Procollagen, type III, alpha 1 Col3a1 12825 1 7.7; 10.4
Procollagen, type V, alpha 2 Col5a2 12832 1 6.2; 10.0
Receptor transporter protein 4 Rtp4 67775 16 11.4; 6.1
Regenerating islet-derived 3 gamma* Reg3g 19695 6 7.9; 21.2
Retinol binding protein 1, cellular Rbp1 19659 9 13.5; 7.6
RIKEN cDNA 1810009J06e 1810009J06Rik 73626 6 160.9; 97.1
Serine (or cysteine) peptidase inhibitor, clade A, member 6 Serpina6 12401 12 18.6; 6.1
Similar to histone 2a MGC73635 665433 13 12.3; 21.3
Stathmin 1 Stmn1 16764 4 11.1; 10.2
Sulfatase 2 Sulf2 72043 2 9.1; 17.3
Tetraspanin 1 Tspan1 66805 4 10.8; 6.0
Thymosin, beta 10 Tmsb10 19240 7 10.1; 8.1
Topoisomerase (DNA) II alpha Top2a 21973 11 11.5; 13.4
TYRO protein tyrosine kinase binding protein Tyrobp 22177 7 22.6; 11.6
Ubiquitin-conjugating enzyme E2C Ube2c 68612 2 12.9; 13.4
Widely-interspaced zinc ﬁnger motif Wiz 22404 17 15.8; 10.0
Galanin Gal 14419 19 21.1; 11.7
Hepcidin antimicrobial peptide 2 Hamp2 66438 7 42.3; 21.0
Inter alpha-trypsin inhibitor, heavy chain 4* Itih4 16427 14 16.8; 12.7
RIKEN cDNA 1810007D17 gene 1810007D17Rik 69055 19 17.7; 10.5
Two pore segment channel 2 Tpcn2 233979 7 14.2; 6.3
Only transcripts that were regulated more than 10-fold in at least one of the substrains (B6J or B6N) are shown. P < 0.01, cerulein-treated versus control
probes. A minus sign in the fold change column indicates downregulation in B6J versus B6N.
*Expressed at signiﬁcantly different level (fold change >2) between B6J and B6N after cerulein treatment in the CP mouse model. P < 0.05.
Cerulein-Induced CP Proﬁlewith cerulein-induced CP in mouse correspond to human
CP proﬁles, we compared the results of our microarray
analysis with a published list of 107 pancreatic human genes
up-regulated in stromal compartments of patients with CP
and pancreatic cancer.33 Of the human genes on that list,
40% were also up-regulated in our cerulein model of mouse
CP. Among these mouse genes were apolipoprotein E
(Apoe); cathepsin K (Ctsk); cathepsin S (Ctss); Fc receptor,
IgE, high afﬁnity I, gamma polypeptide (Fcer1g); lumican
(Lum); lysyl oxidase (Lox); Mmp2; periostin, osteoblastThe American Journal of Pathology - ajp.amjpathol.orgspeciﬁc factor (Postn); and Col1a2, Col3a1, Col5a2, and
Col1a1.
Trypsinogen 5 mRNA (Homolog of Human
Mesotrypsinogen) Is Strongly Up-Regulated in the
Pancreas of Mice with Cerulein-Induced Chronic and
Acute Pancreatitis
Microarray analysis revealed that the 1810009J06Rik tran-
script was the most highly up-regulated gene (up to 160-fold)701
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Figure 8 Pancreatic T5 mRNA expression in B6J and B6N substrains. A:
Pancreatic T5 expression in saline-injected control mice and in repetitive
cerulein-injected mice after induction of CP. T5 expression was signiﬁcantly
induced after induction of CP in both B6N and B6J substrains. B: Pancreatic
T5 expression in mice after acute cerulein-induced injury. Similar to the
increase in CP, T5 mRNA expression was signiﬁcantly induced in both
substrains after acute injury. T5 mRNA expression was normalized to Rplp0
and expressed as fold increase over the level in B6N saline-treated control
mice. Data are expressed as means with 95% conﬁdence intervals. Conﬁ-
dence intervals were calculated using the DCT values before exponential
transformation to fold increase in mRNA and are therefore asymmetric
about the means. n Z 6. *P < 0.05.
Ulmasov et alin the pancreas of mice with CP, in both the B6J and the B6N
substrain. Using NCBI BLAST homology search of human
transcripts, we found that 1810009J06Rik is most closely
related to the human mesotrypsinogen gene (protease, serine,
3; PSSR3), with 75% identity. Mesotrypsinogen is a minor
trypsinogen isoform that is resistant to naturally occurring
trypsin inhibitors. The functional ortholog of human meso-
trypsin in the rat is a protein identiﬁed as P23, and P23
expression in rats is also up-regulated by cerulein. To
determine whether mouse 1810009J06Rik is similar to rat
P23, we compared the sequences of these transcripts and
found that they have 95% sequence identity. All active sites of
rat P23 are preserved in mouse 1810009J06Rik, including the
sequence differences that distinguish it from other trypsin-
ogen isoforms and make P23 resistant to endogenous trypsin
inhibitors. These ﬁndings indicate that 1810009J06Rik is the
mouse homolog of rat P23.
There are 20 trypsinogen genes (T1 to T20) in mouse,
12 of which express trypsinogen proteins.34,35 According
to this classiﬁcation, 1810009J06Rik is identiﬁed as T5.
We did not ﬁnd any signiﬁcant induction in the mRNA
expression of other trypsinogens with repetitive cerulein702treatment. The mRNA of T7, an isoform demonstrated to be
involved in pathological intra-acinar trypsinogen activation
in mice,36 was slightly (1.4-fold) but signiﬁcantly (P Z
0.006) down-regulated. In the pancreas of mice with CP, T5
and T7 mRNA were expressed at similar levels. The result of
microarray analysis of T5 mRNA expression was validated
by RT-qPCR analysis. The expression of T5 mRNA was
induced more than 1000-fold in the repetitive cerulein model
of CP (Figure 8A). Because the severity of cerulein-induced
acute pancreatitis episodes may determine the severity of the
resulting CP phenotype, we evaluated whether cerulein
induces T5 expression in the acute pancreatitis model and
found that T5mRNA is also strongly up-regulated, in the acute
pancreatitis model, similar to the CP model (Figure 8B).
Two Members of the Chemokine (C-C Motif) Family of
Ligands, Ccl8 and Ccl6, Are Strongly Up-Regulated in
the Pancreas of Mice with Cerulein-Induced CP
Chemokines are involved in the pathogenesis of inﬂam-
matory and ﬁbrotic diseases, including CP. A number of
cytokines and chemokines were differentially regulated after
repetitive cerulein treatment, as determined by microarray
analysis. Among these, two chemokines were up-regulated
the most: chemokine (C-C motif) ligand 8 [Ccl8; alias
monocyte chemoattractant protein 2 (MCP-2)]) and che-
mokine (C-C motif) ligand 6 (Ccl6). In fact, Ccl8 was the
second most highly regulated gene in the microarray (after
T5) (Table 5). Microarray data for Ccl8 were evaluated by
qPCR analysis (Figure 9A). The B6J substrain demonstrated
higher Ccl8 mRNA expression than the B6N substrain in
microarray analysis (P < 0.05), but with only a trend toward
higher expression in qPCR analysis (P Z 0.2). The
expression of Ccl8 mRNA after induction of acute pancre-
atitis was much lower, with only an approximately 2.5-fold
increase, only in the B6J substrain (Figure 9B).
Genes with Differentially Regulated Expression
between B6J and B6N Mice with CP Are Identiﬁed as
Potential Candidate Genes in the Development of CP
Based on the differences in the course of CP between B6J
and B6N substrains, we sought to identify genes within the
most differentially regulated microarray data (deﬁned by
P < 0.01 and average fold change of >2) that were asso-
ciated with the differences in the disease severity. Using this
approach, we identiﬁed nine genes differentially expressed
between normal pancreas and CP and between B6J and B6N
substrains after induction of CP (Table 6). Of these genes,
ﬁve were up-regulated in the B6J substrain that develops
more severe CP, compared with the B6N substrain, and the
other four were down-regulated.
One of the genes that was up-regulated in CP and further
up-regulated in the B6J substrain was procollagen C-endo-
peptidase enhancer 2 (Pcolce2). Collagen is secreted as
a soluble procollagen molecule with C- and N-terminalajp.amjpathol.org - The American Journal of Pathology
R
e
l
a
t
i
v
e
 
C
c
l
8
 
m
R
N
A
 
e
x
p
r
e
s
s
i
o
n
0
20
40
60
80
100
120
140
B6N B6J
Saline Cerulein 
B6N B6J
*
*
R
e
l
a
t
i
v
e
 
C
c
l
8
 
m
R
N
A
 
e
x
p
r
e
s
s
i
o
n
0
1
2
3
4
5
B6N B6J B6N B6J
Saline Cerulein 
*
*
*
Figure 9 Pancreatic Ccl8 expression in B6J and B6N substrains. A: Ccl8
expression in the pancreas after induction of CP. Ccl8 was strongly up-
regulated in the pancreas of mice with CP, compared with control mice.
The up-regulation in B6J mice was not signiﬁcantly greater than in B6N
mice (P Z 0.02). B: Ccl8 expression in the pancreas after acute cerulein-
induced injury. Acute injury induced Ccl8 mRNA increase approximately
2.5-fold in B6J mice, but not in B6N mice. Ccl8 mRNA expression was
normalized to Rplp0 and expressed as fold increase over the level in B6N
saline-treated control mice. Data are expressed as means with 95% conﬁ-
dence intervals. Conﬁdence intervals were calculated using the DCT values
before exponential transformation to fold increase in mRNA and are
therefore asymmetric about the means. n Z 6. *P < 0.05.
Cerulein-Induced CP Proﬁlepropeptides attached. Enzymatic cleavage of C-terminal
propeptide by bone morphogenic protein 1 (BMP-1) is
required for collagen incorporation into insoluble collagen
ﬁbrils.37 The Pcolce2 protein enhances catalytic activity of
BMP-1 for ﬁbrillar collagen formation.38 Thus, Pcolce2
could be a factor responsible for the increased collagen
accumulation in B6J mice. Although there are no data in the
literature on the role of Pcolce2 in pancreatic ﬁbrosis,
Pcolce2-deﬁcient mice exhibited decreased collagen depo-
sition in myocardium of pressure overloaded mice.39
Another highly induced and differentially regulated gene
identiﬁed on the microarrays, Mmp7 (which encodes matrily-
sin) has been reported to play an essential role in the devel-
opment of CP in an obstructive pancreatitis mouse model.40
Mmp7 protein levels are also highly up-regulated in human
and mouse pancreatic ductal adenocarcinomas and noninva-
sive ductal precursors, and Mmp7 expression is necessary for
pancreatic ductal adenocarcinoma progression.41
We identiﬁed inter a-trypsin inhibitor, heavy chain 4
(Itih4) as a gene differentially expressed between substrains
in both normal pancreas (Table 4) and in the pancreas
of mice with CP (Table 6) (B6N > B6J). Itih4 mRNA
expression was markedly down-regulated after repetitive
cerulein treatment (Table 5). The precise function of the
Itih4 protein is not known. Studies have shown that Itih4
can bind to hyaluronan and thereby stabilize extracellular
matrix,42 and Itih4 has also been proposed as a new serum
biomarker for liver ﬁbrosis in hepatitis C patients, because
it was strongly down-regulated in the blood in patients
with cirrhosis.43 To validate our microarray results, we
performed qPCR analysis of Itih4 mRNA expression in
mouse pancreas before and after the repetitive cerulein
injury (Figure 7A). The results conﬁrmed differential
expression of Itih4 mRNA between the substrains and
signiﬁcant down-regulation of Itih4 expression in the
pancreas of mice with CP. To evaluate whether Itih4 mRNA
expression changes in acute pancreatitis, we performed
qPCR analysis of mouse pancreas mRNA before and after
acute pancreatic injury (Figure 7B). Acute pancreatic injury
did not change pancreatic expression of Itih4 mRNA.
Another potential candidate gene identiﬁed in our screen
that could be essential for the development of pancreatic
ﬁbrosis was vitronectin (Vtn). We demonstrated strong
down-regulation of Vtn in the pancreas of mice with CP,
with more down-regulation in B6J than B6N mice. Vtn is an
abundant component of extracellular matrix and promotes
cell adhesion and spreading. Vtn binds to plasminogen
activator inhibitor 1 (PAI-1), an important modulator of
ﬁbrotic diseases, and stabilizes its activity.44 Its role in
pancreatic ﬁbrogenesis, however, is not known. In support
of our ﬁnding of striking decreases of Vtn mRNA expres-
sion in CP mouse pancreas, recent proteomic studies of
human formalin-ﬁxed, parafﬁn-embedded tissues from
normal pancreas and pancreatic tissues from patients with
CP identiﬁed Vtn as a protein expressed exclusively in
normal tissues.45The American Journal of Pathology - ajp.amjpathol.orgOne more gene of potential importance identiﬁed in our
screening is the WD repeat and FYVE domain containing
1 gene (Wdfy1) (Tables 4 and 6). Little information is
available in the literature about the functions of Wdfy1, but
recently Wdfy1 was identiﬁed in microarray studies as
a candidate gene inﬂuencing alcohol consumption in mice.9
Expression of CP Candidate Genes in PSCs Isolated
from B6N and B6J Substrains
Because the differences in the severity of CP between B6N
and B6J substrains were not related to the degree of acute
injury, but rather from subsequent processes, and that PSCs
are the main cell type responsible for ﬁbrogenesis in the
pancreas, substrain-speciﬁc differential gene expression in
PSCs could be responsible for the observed alterations. We
therefore examined whether genes identiﬁed in the whole
pancreas as potential candidates important in CP develop-
ment are differentially expressed in PSCs isolated from B6N
and B6J substrains. To obtain enough cells for the RT-qPCR
mRNA analysis, cells were propagated and activated by
culturing on plastic culture plates. mRNA expression of
Mmp7, Pcolce2, Itih4, Vtn, Wdfy1, C4b, and Ccl8 were
measured in PSCs isolated from B6N and B6J mice.703
Table 6 Differential Expression of Pancreatic Genes Between B6J and B6N Mouse Substrains after the Induction of CP
Gene Gene symbol EntrezGene ID Chr
Fold difference
B6J vs B6N
Interferon-induced protein with tetratricopeptide repeats 1 Iﬁt1 15957 19 3.8
Matrix metallopeptidase 7 Mmp7 17393 9 3.5
Placenta speciﬁc 9 Plac9 211623 14 3.4
Transmembrane protein 27 Tmem27 57394 X 2.3
Procollagen C-endopeptidase enhancer 2 Pcolce2 76477 9 2.0
Inter alpha-trypsin inhibitor, heavy chain 4 Itih4 16427 14 4.8
WD repeat and FYVE domain containing 1 Wdfy1 69368 1 4.6
Neurofascin Nfasc 269116 1 2.7
Vitronectin Vtn 22370 11 2.6
A transcript was considered to be highly signiﬁcantly divergently expressed between B6J and B6N substrains if the P value between strains was <0.01 and
the average fold change was >2. A minus sign in the fold difference column indicates lower mRNA abundance in B6J versus B6N.
Ulmasov et alExpression of Itih4 and Mmp7 was essentially undetectable
in PSCs by qPCR. The other genes were all expressed at
similar levels in the two substrains (data not shown), except
Wdfy1. PSCs isolated from B6N expressed threefold more
Wdfy1 mRNA, compared with PSCs isolated from B6J
(Figure 10), which is similar to the differential expression
found in the whole-pancreas microarray data. We also
assessed mRNA expression of vimentin and a-SMA as
markers of PSC identity and activation, respectively, and
found no difference in the expression of these genes
between B6N and B6J (data not shown).R
e
l
a
t
i
v
e
 
W
d
f
y
1
 
m
R
N
A
 
e
x
p
r
e
s
s
i
o
n
0.0
0.2
0.4
0.6
0.8
1.0
1.2
*
B6N - PSC B6J - PSC
Figure 10 Wdfy1 mRNA expression in PSCs isolated from B6N and B6J
substrains. Wdfy1 mRNA expression was normalized to Rplp0 and expressed
as fold change over the level in PSCs isolated from B6N mice. Data are
expressed as means (n Z 3) with 95% conﬁdence intervals. Conﬁdence
intervals were calculated using the DCT values before exponential trans-
formation to fold increase in mRNA and are therefore asymmetric about the
means. *P < 0.05.Discussion
CP is a devastating disease, and the mechanisms involved in
CP development are actively being studied. A well-
developed model of CP recapitulating human disease is
the use of repetitive cerulein injection in mice. The C57BL/
6 mouse is the most common inbred mouse strain used in
biomedical research, and it is a preferred strain for the prop-
agation of knockout and transgenic mice. The wide demand
for this strain has led to the creation and maintenance of
multiple separate colonies of C57BL/6 in different facilities
for many decades, resulting in substrains of C57BL/6. These
substrains are often used interchangeably in experiments, on
the assumption that they are genetically identical. Recently,
however, data have begun to accumulate that important
differences exist in the phenotypes and genotypes of these
very similar substrains. Some of the reported phenotypic
differences between C57BL/6 substrains include variations
in behavior,8 alcohol consumption and alcohol preference,9
glucose homeostasis,12 and response to liver injury.7
Genetic differences among substrains include genomic copy
number variations,10 single-nucleotide polymorphisms,11,46
and spontaneous deletions and mutations.12,13,47
Here, we have reported striking differences in the course
of cerulein-induced CP between the B6J substrain from the
Jackson Laboratory and the B6N substrain from Harlan
Laboratories. C57BL/6 mouse colonies have been bred in
these separate facilities for more than six decades. Features704of repetitive cerulein-induced CP such as pancreatic
atrophy, inﬂammatory cell inﬁltration, and ﬁbrosis were
signiﬁcantly more severe in B6J than in B6N mice
(Figures 1, 2, and 3), whereas the response to acute injury
was similar between the substrains (Figure 4). This obser-
vation led us to test speciﬁc hypotheses and obtain a large
body of data to explore additional genotypeephenotype
associations. These important ﬁndings are also relevant to
pancreatitis research and to investigations in other ﬁelds,
because most investigators treat different C57BL/6 sub-
strains as identical, often reducing the identiﬁer simply to
C57, B6, or C57 black. If transgenic or knockout mice used
in studies are generated on a C57BL/6 background and
control mice on a C57BL/6 substrain, then the experimental
results could be misleading. It is also critically important to
identify the exact genetic background of genetically engi-
neered mice; some mice may have mixed backgrounds,
because C57BL/6 mice obtained from different commercial
sources sometimes coexist in animal core facilities.
Although the presence of genotypic and phenotypic
differences between substrains may, if ignored, lead to
misinterpretation of experimental results, the divergenceajp.amjpathol.org - The American Journal of Pathology
Cerulein-Induced CP Proﬁleamong genetically closely related mouse strains or sub-
strains also presents an opportunity to identify genes that
may contribute to disease development and progression.9,48
In the present study, we examined the potential role of NNT
in chronic and acute pancreatitis, because B6J mice lack
functional NNT12,13 and because NNT may play an
important role in preventing mitochondrial oxidative stress.13
Because mitochondrial oxidative stress plays a pathological
role in pancreatitis,16,17 we hypothesized that B6J mice have
a more severe CP phenotype because of the absence of NNT.
However, we did not ﬁnd any differences in the parameters of
CP between transgenic Nntþ/þB6J mice and the control mice
lacking NNT. Because the level of expression of NNT in the
mitochondria of transgenic mice was similar to that in B6N
mice (Figure 5), and because transgenic NNT had been
previously demonstrated to be a functional protein,23 we
concluded that the loss of NNT is not the sole factor under-
lying the observed phenotypic differences between B6J and
B6N mice. However, our experiment cannot exclude the
possibility of more complex geneegene interactions, in
which loss of NNT and other differences in gene expression
between the two substrains combine to cause the more severe
phenotype in the B6J substrain. Interestingly, two substrains
of C57BL/6 mice, one with an Nnt mutation and the other
without, were recently compared in two models of liver
injury; the authors reported that, to their surprise, the sub-
strain with functional NNT expression hadmore liver injury.7
Further work is clearly needed to better understand the
functional consequences of the loss of NNT in B6J mice.
To identify genes associated with cerulein-induced CP and
to understand the genetic factors responsible for observed
differences in the degree of CP between B6J and B6N sub-
strains, we performed a microarray gene expression analysis
of pancreatic mRNAs from B6J and B6N substrains with and
without CP using a whole mouse genome Affymetrix chip.
Comparison of pancreatic mRNAs of B6J and B6N sub-
strains treated only with saline revealed that, although most
genes were expressed at similar levels between the two
substrains, several genes in addition to Nnt were differen-
tially expressed (Table 4). Corroborating our ﬁndings, two
genes with differential expression between the substrains in
normal pancreas in our microarray analysis (Entpd4 and
Wdfy1) were also found in another study to be differentially
regulated in the brain in B6J and C57BL/6NCrl (Charles
River Laboratories, Wilmington, MA) substrains.9
Induction of CP with repeated cerulein treatment caused
signiﬁcant differential regulation (w7.7%) of a large
number of genes in both substrains. Our pancreatic gene
expression proﬁle associated with CP in the mouse can
serve as a valuable data set for understanding some of the
contributing factors to CP development and progression.
The most highly differentially regulated genes are listed in
Table 5. An interesting result was the ﬁnding that mouse T5
(1810009J06Rik) is strongly up-regulated in CP. This
mouse trypsinogen isoform is expressed at very low levels
in normal pancreas, but it was increased almost 1000-foldThe American Journal of Pathology - ajp.amjpathol.orgafter induction of chronic as well as acute pancreatitis
(Figure 8). We identiﬁed T5 as the mouse ortholog of
human mesotrypsinogen and of the P23 protein in rats.
Importantly, mesotrypsin and P23 are trypsins that are
resistant to naturally occurring trypsin inhibitors.49 The
identiﬁcation of a new trypsin-resistant form of trypsinogen
in the mouse during pancreatic injury could be important,
because an imbalance of pancreatic proteases, and in
particular the trypsin isoforms and their speciﬁc inhibitors,
is thought to play a central role in the pathogenesis of both
chronic and acute pancreatitis.1 Patients with acute pancre-
atitis were recently found to have signiﬁcantly increased
serum levels of mesotrypsinogen.50 The mRNA for T5 was
also reported by Hayashi et al35 to be up-regulated
approximately 1000-fold in mouse pancreas lacking inter-
feron regulatory factor 2 (Irf2). Interestingly, Irf2/ mice
were reported to have a defect in pancreatic endocytosis,51
and treatment of these mice with synthetic double-
stranded DNA caused severe acute pancreatitis and death
within 1 week of treatment. Further studies are needed to
elucidate the role of T5 in chronic and acute pancreatitis.
Another important group of genes involved in the
mechanism of CP encode chemokines. Chemokines play an
important role in the inﬂammatory response to tissue injury,
and changes in serum chemokine levels could also be useful
as diagnostic markers in early detection of CP.52 A number
of chemokines were up-regulated in the microarray; among
these, two members of chemokine (C-C motif) family of
ligands, Ccl8 and Ccl6, were highly up-regulated (up to 60-
fold in B6J mice) (Table 4). Moreover, Ccl8 was up-
regulated to a greater extent in the pancreas of B6J mice
than in that of B6N mice, indicating the possibility of its
involvement in the mechanism of the more severe CP
phenotype of B6J substrain mice (Figure 9A). Acute injury
did not cause up-regulation of Ccl8 mRNA in B6N; in B6J,
it caused slight, approximately twofold, up-regulation. Ccl8
and Ccl6 are not well characterized functionally in the
mouse and have not previously been associated with CP.
Because the severity of CP differed between B6J and
B6N but there were no differences in the parameters of acute
injury between the substrains (Figures 3 and 4), we
hypothesize that the genes that are differentially regulated in
CP between the two substrains could be important in the
pathogenesis of pancreatic ﬁbrogenesis, either as factors
contributing to causation or the consequence of the severity
of injury. In our microarray analysis, we identiﬁed nine
genes signiﬁcantly differentially regulated in CP and with
different expression levels between the two substrains
(Table 6). In support of our ﬁndings, one gene from this list,
Mmp7, was reported to be involved in the pathology of CP
in a CP model caused by surgical ligation of the main
pancreatic duct.40 Several other genes have been reported to
participate in the ﬁbrotic mechanisms in other organs. For
example, the Pcolce2 gene product was found to be required
for the efﬁcient collagen processing and deposition of
myocardial ﬁbrillar collagen in a chronic pressure overload705
Ulmasov et almodel.39 Pcolce2 is an enhancer of collagen synthesis, and
its role in pancreatic ﬁbrogenesis is not known. The mRNA
of Pcolce2 was induced approximately ﬁvefold after
induction of CP in B6J.
Another of our nine genes, Vtn, is reported to be asso-
ciated with ﬁbrotic diseases. An abundant protein found in
serum and in extracellular matrix, Vtn promotes cell adhe-
sion and spreading by multiple mechanisms. Vtn has a high
binding afﬁnity for the potent ﬁbrosis-promoting molecule
PAI-1, and its expression was found to be closely associated
with ﬁbrosis in ﬁbrotic liver and lung diseases.53,54 In the
kidney, Vtn can both increase and attenuate ﬁbrogenesis,
depending on the model, suggesting that its net effect is
regulated by local environmental factors.55 In contrast to
liver ﬁbrosis, in our repetitive cerulein model of CP the
expression of Vtn mRNA was strongly down-regulated
(w6.6-fold in B6J). In support of our ﬁndings, human
pancreatic tissues from CP patients were also reported to
have decreased Vtn expression.45
Another interesting candidate gene identiﬁed in our
microarray analysis is Itih4. Its mRNA expression is higher in
normal pancreas of B6N, compared with B6J (Table 4),
raising the possibility that Itih4 could play a protective role.
In both substrains, pancreatic expression of Itih4 decreased
dramatically after CP induction (Table 5), with B6N ex-
pression remaining higher than B6J (Table 6). Itih4 belongs
to the subfamily of Kunitz-type protease inhibitors. Five
members of this family (Itih1 through Itih5) have been iso-
lated in mice, and all have human homologs. Itih1, Itih2, and
Itih3 are plasma glycoproteins assembled in the liver from
heavy chains encoded by separate genes and from a light
chain, designated bikunin. Proteinase activity of Itih proteins
resides solely in the bikunin part of the molecule.56 Itih4 does
not have a site for binding with bikunin and therefore exists
as a free heavy chain polypeptide. Although Itih5 has all of
the necessary features for bikunin binding, the existence of
the complex with bikunin has not yet been demonstrated. In
our microarray analysis, Itih5 mRNA level signiﬁcantly
increased after induction of CP, with no alteration for the
other Itih genes, indicating possibly different roles of these
proteins in pancreatitis. The functions of these proteins are
not clear, but they may be involved in the stabilization of
extracellular matrix by binding hyaluronan.42 Itih4 was re-
ported to be highly inducible by IL-6 in regenerating mouse
livers, and it is considered to be an acute-phase protein in
several animal models for liver.57 At the same time, Itih4 has
been shown to be decreased in the serum of patients with
hepatitis C cirrhosis43 and in multiple human solid tumors.58
The role of Itih4 in the pancreas has not been studied,
although Itih4 mRNA is expressed in human pancreas at
a level second only to the liver in abundance.58
Because we established that the differences in the course
of CP arose during the process of ﬁbrogenesis and not from
the degree of acute injury, and given that PSCs are the
primary source of pancreatic ﬁbrosis, differences in the
expression of genes in PSCs might be responsible for the706observed substrain differences in CP. In the normal
pancreas, PSCs comprise only approximately 4% of the total
pancreatic cells; after induction of CP, however, PSCs are
activated, proliferate, and acquire a myoﬁbroblast pheno-
type.3 Analysis of the microarray results after induction of
CP did not reveal any difference between B6N and B6J
substrains in the mRNA expression of genes commonly
attributed to PSC activation, such as a-SMA or the pro-
collagens. To determine whether differentially expressed
genes in the whole pancreas would be differentially
expressed in PSCs isolated from B6N and B6J mice, we
isolated and cultured activated PSCs from these substrains.
Wdfy1 mRNA was expressed at signiﬁcantly lower levels in
PSCs from B6J than from B6N (Figure 10). Further research
will be needed to evaluate whether changes in Wdfy1
mRNA expression lead to the changes in protein expression,
morphology, proliferation, or ﬁbrotic responses of PSCs.
In conclusion, with the present study we have identiﬁed
substantial phenotypic differences in the course of cerulein-
induced CP in B6J and B6N substrains of C57BL/6 mice.
Although NNT is absent in B6J mice, we could not impli-
cate its absence in causing a more severe CP phenotype.
Using whole mouse genome Affymetrix microarray anal-
ysis, we identiﬁed pancreatic transcripts that are associated
with the development of CP in mice. Using the B6J and
B6N substrains, we have provided a data set for future
studies of pancreatic ﬁbrogenesis. Novel transcripts associ-
ated with CP identiﬁed in the present study include T5,
Ccl8, and Ccl6. Finally, by comparing B6J and B6N
microarrays, we identiﬁed a small subset of potential gene
candidates implicated in a more severe phenotype of CP,
including Mmp7, Pcolce2, Itih4, Wdfy1, and Vtn. The
phenotypic substrain differences and differential gene
expression demonstrated in this study also highlight the
need to accurately recognize and report the substrain
background of C57BL/6 mice used in research and also to
avoid the substrain mispairing (likely a common error in the
past) that could lead to incorrect interpretation of results.
References
1. Witt H, Apte MV, Keim V, Wilson JS: Chronic pancreatitis: chal-
lenges and advances in pathogenesis, genetics, diagnosis, and
therapy. Gastroenterology 2007, 132:1557e1573
2. Nair RJ, Lawler L, Miller MR: Chronic pancreatitis. Am Fam
Physician 2007, 76:1679e1688
3. OmaryMB,LugeaA, LoweAW,Pandol SJ: The pancreatic stellate cell:
a star on the rise in pancreatic diseases. J Clin Invest 2007, 117:50e59
4. Aghdassi AA, Mayerle J, Christochowitz S, Weiss FU, Sendler M,
Lerch MM: Animal models for investigating chronic pancreatitis.
Fibrogenesis Tissue Repair 2011, 4:26
5. Neuschwander-Tetri BA, Burton FR, Presti ME, Britton RS,
Janney CG, Garvin PR, Brunt EM, Galvin NJ, Poulos JE: Repetitive
self-limited acute pancreatitis induces pancreatic ﬁbrogenesis in the
mouse. Dig Dis Sci 2000, 45:665e674
6. Neuschwander-Tetri BA, Bridle KR, Wells LD, Marcu M,
Ramm GA: Repetitive acute pancreatic injury in the mouse induces
procollagen alpha1(I) expression colocalized to pancreatic stellate
cells. Lab Invest 2000, 80:143e150ajp.amjpathol.org - The American Journal of Pathology
Cerulein-Induced CP Proﬁle7. Bourdi M, Davies JS, Pohl LR: Mispairing C57BL/6 substrains of
genetically engineered mice and wild-type controls can lead to con-
founding results as it did in studies of JNK2 in acetaminophen and
concanavalin A liver injury. Chem Res Toxicol 2011, 24:794e796
8. Bryant CD, Zhang NN, Sokoloff G, Fanselow MS, Ennes HS,
Palmer AA, McRoberts JA: Behavioral differences among C57BL/6
substrains: implications for transgenic and knockout studies. J Neu-
rogenet 2008, 22:315e331
9. Mulligan MK, Ponomarev I, Boehm SL 2nd, Owen JA, Levin PS,
Berman AE, Blednov YA, Crabbe JC, Williams RW, Miles MF,
Bergeson SE: Alcohol trait and transcriptional genomic analysis of
C57BL/6 substrains. Genes Brain Behav 2008, 7:677e689
10. Watkins-Chow DE, Pavan WJ: Genomic copy number and expres-
sion variation within the C57BL/6J inbred mouse strain. Genome Res
2008, 18:60e66
11. Zurita E, Chagoyen M, Cantero M, Alonso R, Gonzalez-Neira A,
Lopez-Jimenez A, Lopez-Moreno JA, Landel CP, Benitez J, Pazos F,
Montoliu L: Genetic polymorphisms among C57BL/6 mouse inbred
strains. Transgenic Res 2011, 20:481e489
12. Toye AA, Lippiat JD, Proks P, Shimomura K, Bentley L, Hugill A,
Mijat V, Goldsworthy M, Moir L, Haynes A, Quarterman J,
Freeman HC, Ashcroft FM, Cox RD: A genetic and physiological
study of impaired glucose homeostasis control in C57BL/6J mice.
Diabetologia 2005, 48:675e686
13. Huang TT, Naeemuddin M, Elchuri S, Yamaguchi M, Kozy HM,
Carlson EJ, Epstein CJ: Genetic modiﬁers of the phenotype of mice
deﬁcient in mitochondrial superoxide dismutase. Hum Mol Genet
2006, 15:1187e1194
14. Arkblad EL, Tuck S, Pestov NB, Dmitriev RI, Kostina MB,
Stenvall J, Tranberg M, Rydström J: A Caenorhabditis elegans
mutant lacking functional nicotinamide nucleotide transhydrogenase
displays increased sensitivity to oxidative stress. Free Radic Biol Med
2005, 38:1518e1525
15. Freeman H, Shimomura K, Horner E, Cox RD, Ashcroft FM:
Nicotinamide nucleotide transhydrogenase: a key role in insulin
secretion. Cell Metab 2006, 3:35e45
16. Mukherjee R, Criddle DN, Gukovskaya A, Pandol S, Petersen OH,
Sutton R: Mitochondrial injury in pancreatitis. Cell Calcium 2008,
44:14e23
17. Odinokova IV, Sung KF, Mareninova OA, Hermann K, Gukovsky I,
Gukovskaya AS: Mitochondrial mechanisms of death responses in
pancreatitis. J Gastroenterol Hepatol 2008, 23(Suppl 1):S25eS30
18. Ulmasov B, Xu Z, Talkad V, Oshima K, Neuschwander-Tetri BA:
Angiotensin II signaling through the AT1a and AT1b receptors does
not have a role in the development of cerulein-induced chronic
pancreatitis in the mouse. Am J Physiol Gastrointest Liver Physiol
2010, 299:G70eG80
19. Ulmasov B, Xu Z, Tetri LH, Inagami T, Neuschwander-Tetri BA:
Protective role of angiotensin II type 2 receptor signaling in a mouse
model of pancreatic ﬁbrosis. Am J Physiol Gastrointest Liver Physiol
2009, 296:G284eG294
20. French SW, Miyamoto K, Wong K, Jui L, Briere L: Role of the Ito
cell in liver parenchymal ﬁbrosis in rats fed alcohol and a high fat-low
protein diet. Am J Pathol 1988, 132:73e85
21. Mareninova OA, Sung KF, Hong P, Lugea A, Pandol SJ, Gukovsky I,
Gukovskaya AS: Cell death in pancreatitis: caspases protect from
necrotizing pancreatitis. J Biol Chem 2006, 281:3370e3381
22. Bai H, Chen X, Zhang L, Dou X: The effect of sulindac, a non-
steroidal anti-inﬂammatory drug, attenuates inﬂammation and
ﬁbrosis in a mouse model of chronic pancreatitis. BMC Gastroenterol
2012, 12:115
23. Freeman HC, Hugill A, Dear NT, Ashcroft FM, Cox RD: Deletion of
nicotinamide nucleotide transhydrogenase: a new quantitive [sic] trait
locus accounting for glucose intolerance in C57BL/6J mice. Diabetes
2006, 55:2153e2156
24. Wang X, Seed B: A PCR primer bank for quantitative gene expres-
sion analysis. Nucleic Acids Res 2003, 31:e154The American Journal of Pathology - ajp.amjpathol.org25. Lugea A, Gukovsky I, Gukovskaya AS, Pandol SJ: Nonoxidative
ethanol metabolites alter extracellular matrix protein content in rat
pancreas. Gastroenterology 2003, 125:1845e1859
26. Gukovsky I, Gukovskaya AS, Blinman TA, Zaninovic V, Pandol SJ:
Early NF-kappaB activation is associated with hormone-induced
pancreatitis. Am J Physiol 1998, 275:G1402eG1414
27. Perides G, Tao X, West N, Sharma A, Steer ML: A mouse model of
ethanol dependent pancreatic ﬁbrosis. Gut 2005, 54:1461e1467
28. Livak KJ, Schmittgen TD: Analysis of relative gene expression data
using real-time quantitative PCR and the 2(-Delta Delta C(T))
method. Methods 2001, 25:402e408
29. Huang da W, Sherman BT, Lempicki RA: Systematic and integrative
analysis of large gene lists using DAVID bioinformatics resources.
Nat Protoc 2009, 4:44e57
30. Edgar R, Domrachev M, Lash AE: Gene Expression Omnibus: NCBI
gene expression and hybridization array data repository. Nucleic
Acids Res 2002, 30:207e210
31. Yuan JS, Reed A, Chen F, Stewart CN Jr: Statistical analysis of real-
time PCR data. BMC Bioinformatics 2006, 7:85
32. Shimomura K, Galvanovskis J, Goldsworthy M, Hugill A, Kaizak S,
Lee A, Meadows N, Quwailid MM, Rydstrom J, Teboul L,
Ashcroft F, Cox RD: Insulin secretion from beta-cells is affected by
deletion of nicotinamide nucleotide transhydrogenase. Methods
Enzymol 2009, 457:451e480
33. Binkley CE, Zhang L, Greenson JK, Giordano TJ, Kuick R, Misek D,
Hanash S,LogsdonCD, SimeoneDM:Themolecular basis of pancreatic
ﬁbrosis: common stromal gene expression in chronic pancreatitis and
pancreatic adenocarcinoma. Pancreas 2004, 29:254e263
34. Spicuglia S, Pekowska A, Zacarias-Cabeza J, Ferrier P: Epigenetic
control ofTcrb gene rearrangement. Semin Immunol 2010, 22:330e336
35. Hayashi H, Kohno T, Yasui K, Murota H, Kimura T, Duncan GS,
Nakashima T, Yamamoto K, Katayama I, Ma Y, Chua KJ,
Suematsu T, Shimokawa I, Akira S, Kubo Y, Mak TW,
Matsuyama T: Characterization of dsRNA-induced pancreatitis model
reveals the regulatory role of IFN regulatory factor 2 (Irf2) in tryp-
sinogen5 gene transcription. Proc Natl Acad Sci USA 2011, 108:
18766e18771
36. Dawra R, Sah RP, Dudeja V, Rishi L, Talukdar R, Garg P,
Saluja AK: Intra-acinar trypsinogen activation mediates early stages
of pancreatic injury but not inﬂammation in mice with acute
pancreatitis. Gastroenterology 2011, 141:2210e2217.e2
37. Kessler E, Takahara K, Biniaminov L, Brusel M, Greenspan DS:
Bone morphogenetic protein-1: the type I procollagen C-proteinase.
Science 1996, 271:360e362
38. Steiglitz BM, Keene DR, Greenspan DS: PCOLCE2 encodes
a functional procollagen C-proteinase enhancer (PCPE2) that is
a collagen-binding protein differing in distribution of expression and
post-translational modiﬁcation from the previously described PCPE1.
J Biol Chem 2002, 277:49820e49830
39. Baicu CF, Zhang Y, Van Laer AO, Renaud L, Zile MR,
Bradshaw AD: Effects of the absence of procollagen C-endopeptidase
enhancer-2 on myocardial collagen accumulation in chronic pressure
overload. Am J Physiol Heart Circ Physiol 2012, 303:H234eH240
40. Crawford HC, Scoggins CR, Washington MK, Matrisian LM,
Leach SD: Matrix metalloproteinase-7 is expressed by pancreatic
cancer precursors and regulates acinar-to-ductal metaplasia in
exocrine pancreas. J Clin Invest 2002, 109:1437e1444
41. Fukuda A, Wang SC, Morris JP 4th, Folias AE, Liou A, Kim GE,
Akira S, Boucher KM, Firpo MA, Mulvihill SJ, Hebrok M: Stat3 and
MMP7 contribute to pancreatic ductal adenocarcinoma initiation and
progression. Cancer Cell 2011, 19:441e455
42. Zhuo L, Hascall VC, Kimata K: Inter-alpha-trypsin inhibitor,
a covalent protein-glycosaminoglycan-protein complex. J Biol Chem
2004, 279:38079e38082
43. Gangadharan B, Antrobus R, Dwek RA, Zitzmann N: Novel serum
biomarker candidates for liver ﬁbrosis in hepatitis C patients. Clin
Chem 2007, 53:1792e1799707
Ulmasov et al44. Hertig A, Rondeau E: Plasminogen activator inhibitor type 1: the two
faces of the same coin. Curr Opin Nephrol Hypertens 2004, 13:39e44
45. Paulo JA, Lee LS, Banks PA, Steen H, Conwell DL: Proteomic analysis
of formalin-ﬁxed parafﬁn-embedded pancreatic tissue using liquid
chromatography tandemmass spectrometry. Pancreas2012, 41:175e185
46. Mekada K, Abe K, Murakami A, Nakamura S, Nakata H,
Moriwaki K, Obata Y, Yoshiki A: Genetic differences among
C57BL/6 substrains. Exp Anim 2009, 58:141e149
47. Specht CG, Schoepfer R: Deletion of the alpha-synuclein locus in
a subpopulation of C57BL/6J inbred mice. BMC Neurosci 2001, 2:11
48. Grottick AJ, Bagnol D, Phillips S, McDonald J, Behan DP,
Chalmers DT, Hakak Y: Neurotransmission- and cellular stress-
related gene expression associated with prepulse inhibition in mice.
Brain Res Mol Brain Res 2005, 139:153e162
49. Szmola R, Kukor Z, Sahin-Tóth M: Human mesotrypsin is a unique
digestive protease specialized for the degradation of trypsin inhibi-
tors. J Biol Chem 2003, 278:48580e48589
50. Oiva J, Itkonen O, Koistinen R, Hotakainen K, Zhang WM,
Kemppainen E, Puolakkainen P, Kylänpää L, Stenman UH,
Koistinen H: Speciﬁc immunoassay reveals increased serum tryp-
sinogen 3 in acute pancreatitis. Clin Chem 2011, 57:1506e1513
51. Mashima H, Sato T, Horie Y, Nakagawa Y, Kojima I, Ohteki T,
Ohnishi H: Interferon regulatory factor-2 regulates exocytosis
mechanisms mediated by SNAREs in pancreatic acinar cells.
Gastroenterology 2011, 141:1102e1113.e1ee870852. Ito T: Can measurement of chemokines become useful biological and
functional markers of early-stage chronic pancreatitis? J Gastroenterol
2007, 42(Suppl 17):72e77
53. Eklund AG, Sigurdardottir O, Ohrn M: Vitronectin and its relation-
ship to other extracellular matrix components in bronchoalveolar
lavage ﬂuid in sarcoidosis. Am Rev Respir Dis 1992, 145:646e650
54. Koukoulis GK, Shen J, Virtanen I, Gould VE: Vitronectin in the
cirrhotic liver: an immunomarker of mature ﬁbrosis. Hum Pathol
2001, 32:1356e1362
55. López-Guisa JM, Rassa AC, Cai X, Collins SJ, Eddy AA: Vitronectin
accumulates in the interstitium but minimally impacts ﬁbrogenesis in
experimental chronic kidney disease. Am J Physiol Renal Physiol
2011, 300:F1244eF1254
56. Bost F, Diarra-Mehrpour M, Martin JP: Inter-alpha-trypsin inhibitor
proteoglycan familyea group of proteins binding and stabilizing the
extracellular matrix. Eur J Biochem 1998, 252:339e346
57. Bhanumathy CD, Tang Y, Monga SP, Katuri V, Cox JA, Mishra B,
Mishra L: Itih-4, a serine protease inhibitor regulated in interleukin-6-
dependent liver formation: role in liver development and regenera-
tion. Dev Dyn 2002, 223:59e69
58. Hamm A, Veeck J, Bektas N, Wild PJ, Hartmann A, Heindrichs U,
Kristiansen G, Werbowetski-Ogilvie T, Del Maestro R, Knuechel R,
Dahl E: Frequent expression loss of Inter-alpha-trypsin inhibitor
heavy chain (ITIH) genes in multiple human solid tumors: a system-
atic expression analysis. BMC Cancer 2008, 8:25ajp.amjpathol.org - The American Journal of Pathology
